Published in Lab Law Weekly, September 9th, 2005
"This decision will improve patient access to a critically important technology used in the diagnosis of leukemia and lymphoma, the monitoring of viral infection and in detecting and monitoring immune altered states," Alan Mertz, president of ACLA, said.
ACLA presented CMS with updated information derived from laboratory members performing these services. The data detailed clinical staff time involved with the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.